china pharm: die große chance in china - 500 Beiträge pro Seite

[stockbaby]

bin vor ein paar tagen mit 0,24 € eingestiegen. bei den guten zahlen, sollte sich ein investment, vor allem auch trotz der sars-lungenpest lohnen. unter asia-economy.de sind weitere details und empfehlungen zu erfahren!

China Pharamaceutical präsentiert Geschäftszahlen Mittwoch, 26.03.03, 11:17

Die in Hongkong ansässige China Pharamaceutical Corp. hat die Geschäftszahlen für das Gesamtjahr 2002 bekannt gegeben.
Demnach konnte das Unternehmen im Berichtszeitraum einen Nettogewinn in Höhe von 228 Mio. HK-Dollar erwirtschaften. Gegenüber dem Vorjahreszeitraum bedeutet dies eine Steigerung um rund 63 Prozent. Damals stand ein Gewinn von 140 Mio. HK-Dollar in den Büchern. Im Vorfeld der Zahlen hatten Analysten jedoch einen Nettogewinn von rund 231 Mio. HK-Dollar prognostiziert.
Der Umsatz lag in 2002 bei 1,62 Mrd. HK-Dollar nach 1,17 Mrd. HK-Dollar in 2001. Als Gründe der positiven Zahlen nannte das Unternehmen unter anderem die Produktionskosten, die im abgelaufenen Geschäftsjahr weiter gesenkt werden konnten. So wurde durch die Einführung neuer Technologien die Produktionsrate gegenüber dem Vorjahr um rund 14 Prozent gesteigert. Weiter führte der Konzern in diesem Zusammenhang die gestiegenen Preise für Vitamin C-Präparate an.
Die Papiere von China Pharmaceutical beendeten den Handel an der Börse in Hongkong mit einem Abschlag von 3 Prozent bei 1,94 HK-Dollar.

[George_Sand]

Leute, könnt Ihr Euch nicht endlich angewöhnen in einem Aktien-Board mit Euren Aktien-Tips professionell auch die WKN oder andere Möglichkeiten anzugeben um die Aktie mal zu checken:
China Pharamaceutical gibt es nicht laut WO-Suche!

[buflo]

#2
Versuchs mal unter china pharm sonst unter wkn 893291
gruss buflo

[invest2002]

NO.2 vollkaskomentalität deutschland oder einfach zu faul?

invest2002

[stockbaby]

ISIN: HK1093002512 WKN: 893291
oder gib doch einfach china pharm ein. funktioniert auch bei mir!

[Wuscher]

moin moin
Company Research Report

Data as of: 4/4/03

Company Description

China Pharmaceutical Enterprise and Investment Corporation Limited. The Group`s principal activities are the manufacture and sale of pharmaceutical products. The Group is also involved in investment holding. The products of the Group include Vitamin C, Calcium and Sodium ascorbate, penicillin G, ampicillin, amoxicillin and nutraceutical products. The Group`s operations are located in the People`s Republic of China, Africa, Australia, Europe, America and Asia. Penicillin series accounted for 44% of 2001 revenues; 7-ACA series, 30%; Vitamin C series, 24% and others, 2%.


Competitor Analysis
China Pharmaceutical Enterprise and Inve operates within the Pharmaceutical preparations sector. This analysis compares China Pharmaceutical Enterprise and Inve with three other pharmaceutical manufacturers in Australasia: AIN Pharmaciez Inc. of Japan (2002 sales of 24.68 billion Japanese Yen [US$205.56 million] of which 76% was Pharmaceuticals), PT Tempo Scan Pacific of Indonesia (1.97 trillion Indonesian Rupiahs [US$220.58 million] ), and Daewoong Company Limited which is based in South Korea (274.63 billion Korean Won [US$218.33 million] ).


Sales Analysis
During the year ended December of 2002, sales at China Pharmaceutical Enterprise and Inve were HK$1.63 billion (US$208.36 million). This is an increase of 39.1% versus 2001, when the company`s sales were HK$1.17 billion. This was the fifth consecutive year of sales increases at China Pharmaceutical Enterprise and Inve (and since 1997, sales have increased a total of 209%).



Recent Sales at China Pharmaceutical Enterprise and Inve 0.53
0.60
0.82
1.00
1.17
1.63

1997 1998 1999 2000 2001 2002
(Figures in Billions of Hong Kong Dollars)

The company`s sales increased faster in 2002 than at all three comparable companies. While China Pharmaceutical Enterprise and Inve enjoyed a sales increase of 39.1%, the other companies saw smaller increases: AIN Pharmaciez Inc. sales were up 26.1%, PT Tempo Scan Pacific increased 10.3%, and Daewoong Company Limited experienced growth of 20.1%.

The company currently employs 4,310. With sales of HK$1.63 billion (US$208.36 million) , this equates to sales of US$48,343 per employee. This is lower than the three comparable companies, which had sales between US$51,297 and US$495,324 per employee.


Sales Comparisons (Fiscal Year ending 2002) Company Year
Ended
Sales
(US$mlns) Sales
Growth Sales/
Emp (US$) Largest Region
China Pharmaceutical Enterprise and Inve Dec 2002
208.358 39.1% 48,343 N/A
AIN Pharmaciez Inc. Apr 2002 205.559 26.1% 495,324 N/A
PT Tempo Scan Pacific Dec 2002 220.577 10.3% 51,297 N/A
Daewoong Company Limited Mar 2002 218.332 20.1% 234,514 N/A



Recent Stock Performance

The stock price has more than doubled recently: For the 52 weeks ending 4/4/03, the stock of this company was up 141.8% to HK$2.20. During the past 13 weeks, the stock has increased 48.6%. During the past 52 weeks, the stock of China Pharmaceutical Enterprise and Inve has outperformed (by a large margin) the three comparable companies, which saw losses between 19.1% and 76.6%.

During the 12 months ending 12/31/02, earnings per share totalled HK$0.17 per share. Thus, the Price / Earnings ratio is 12.94. These 12 month earnings are greater than the earnings per share achieved during the last fiscal year of the company, which ended in December of 2002, when the company reported earnings of 0.17 per share. Earnings per share rose 47.2% in 2002 from 2001.

This company is currently trading at 1.74 times sales. This is at a higher ratio than all three comparable companies, which are trading between 0.25 and 1.10 times sales. China Pharmaceutical Enterprise and Inve is trading at 1.88 times book value. The company`s price to book ratio is higher than that of all three comparable companies, which are trading between 0.34 and 1.70 times book value.


Summary of company valuations (as of 4/4/03). Company P/E Price/
Book Price/
Sales 52 Wk
Pr Chg
China Pharmaceutical Enterprise and Inve 12.9 1.88 1.74 141.80%
AIN Pharmaciez Inc. 17.2 1.30 0.33 -19.13%
PT Tempo Scan Pacific 6.8 1.70 1.10 -25.00%
Daewoong Company Limited 2.0 0.34 0.25 -76.61%

The market capitalization of this company is HK$2.82 billion (US$361.91 million) . Closely held shares (i.e., those held by officers, directors, pension and benefit plans and those shareholders who own more than 5% of the stock) amount to over 50% of the total shares outstanding: thus, it is impossible for an outsider to acquire a majority of the shares without the consent of management and other insiders. The capitalization of the floating stock (i.e., that which is not closely held) is HK$1.39 billion (US$178.28 million) .


Dividend Analysis
During the 12 months ending 12/31/02, China Pharmaceutical Enterprise and Inve paid dividends totalling HK$0.06 per share. Since the stock is currently trading at HK$2.20, this implies a dividend yield of 2.7%.

During the same 12 month period ended 12/31/02, the Company reported earnings of HK$0.17 per share. Thus, the company paid 35.3% of its profits as dividends.


Profitability Analysis

In 2002, earnings before extraordinary items at China Pharmaceutical Enterprise and Inve were HK$228.14 million, or 14.0% of sales. This profit margin is an improvement over the level the company achieved in 2001, when the profit margin was 12.0% of sales.

The company`s return on equity in 2002 was 17.3%. This was significantly better than the 11.9% return the company achieved in 2001. (Extraordinary items have been excluded

[George_Sand]

Danke an alle für die WPKN.

@invest2002
Wenn meine kritische Bitte von Dir so kommentiert wird scheint es bei einigen im WO doch immer noch nicht weit her zu sein mit der Ernsthaftigkeit beim Thema Börse.
Wirst es schon noch schaffen..bist ja noch jung mit Bezug auf Deine Rhetorik. LOL
Dennoch viel Glück auch Dir beim Investieren.

[skipper2002]

was heißt denn das da oben auf deutsch?????